Gil Young-jun, CEO of Huino; Ham Byung-joo, CEO of Korea University Medical Technology Holdings; Son Ho-sung, Professor of Thoracic Surgery at Korea University Anam Hospital; and Choi Jong-il, Professor of Cardiology at Korea University Anam Hospital (from the fifth person on the left), along with other officials, are posing for a commemorative photo at the joint venture company establishment agreement ceremony. (Photo by Huino)

Gil Young-jun, CEO of Huino; Ham Byung-joo, CEO of Korea University Medical Technology Holdings; Son Ho-sung, Professor of Thoracic Surgery at Korea University Anam Hospital; and Choi Jong-il, Professor of Cardiology at Korea University Anam Hospital (from the fifth person on the left), along with other officials, are posing for a commemorative photo at the joint venture company establishment agreement ceremony. (Photo by Huino)

View original image

[Asia Economy Reporter Chunhee Lee] Digital healthcare company Huino announced on the 26th that it has established a joint venture company with Korea University Medical Technology Holdings.


At the establishment ceremony held on the 22nd at Korea University Mediscience Park, representatives from both companies attended and agreed on the pledge. Professor Hoseong Son of the Department of Thoracic Surgery at Korea University Anam Hospital, who is expected to serve as a board member, and Professor Jongil Choi of the Department of Cardiology at Korea University Anam Hospital, who is expected to serve as Chief Medical Officer (CMO), also attended.


The joint venture company was established for research and development (R&D) purposes to enhance medical productivity by utilizing artificial intelligence (AI) technology on the vast amount of data generated within hospitals. Huino plans to advance its already developed AI-based electrocardiogram interpretation technology to provide better services in medical settings. Through this, they aim to jointly develop digital-based arrhythmia diagnosis technology and integrate Korea University Medical Center’s excellent clinical technology to address AI’s shortcomings, thereby developing global-level medical AI technology.



Gil Youngjun, CEO of Huino, said, “Since AI technology adoption is needed in actual medical settings, and our opinions aligned on this, we established the joint venture company. If we improve the complementary aspects of Huino’s already developed AI technology through the joint venture, we expect not only performance enhancement but also securing highly reliable interpretation technology.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing